Anti-vascular endothelial growth factor (VEGF) therapy normalizes the tumor vasculature, reduces additional VEGF-mediated immunosuppression in the tumor and its microenvironment, and promotes T-cell infiltration (22, 23). This evidence concerns the gene VEGFA and neoplasm.